|
gptkbp:instanceOf
|
gptkb:drug
antidepressant
|
|
gptkbp:activeIngredient
|
gptkb:citalopram
|
|
gptkbp:approvedBy
|
gptkb:FDA
1998
|
|
gptkbp:associatedWith
|
gptkb:escitalopram
|
|
gptkbp:ATCCode
|
N06AB04
|
|
gptkbp:availableOn
|
generic
|
|
gptkbp:contraindication
|
QT prolongation
concurrent use with MAOIs
|
|
gptkbp:drugClass
|
selective serotonin reuptake inhibitor
|
|
gptkbp:eliminatedIn
|
renal
hepatic
|
|
gptkbp:form
|
gptkb:tablet
oral solution
|
|
gptkbp:genericName
|
gptkb:citalopram
|
|
gptkbp:halfLife
|
35 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Celexa
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Lundbeck
gptkb:Forest_Laboratories
|
|
gptkbp:metabolism
|
gptkb:CYP2C19
gptkb:CYP2D6
gptkb:CYP3A4
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:riskFactor
|
gptkb:serotonin_syndrome
suicidal thoughts (in young adults)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
insomnia
dry mouth
sexual dysfunction
somnolence
increased sweating
|
|
gptkbp:tradeNameIn
|
gptkb:United_States
|
|
gptkbp:usedFor
|
gptkb:major_depressive_disorder
anxiety disorders
|
|
gptkbp:bfsParent
|
gptkb:citalopram
|
|
gptkbp:bfsLayer
|
6
|